Group 1 - The article discusses Tourmaline Bio (NASDAQ: TRML) and its focus on advancing beyond FcRn inhibition by targeting IL-6 [2] - The author operates the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and includes a library of over 600 biotech investing articles [2] - The service offers a model portfolio of more than 10 small and mid-cap stocks, along with live chat and various analysis and news reports to assist healthcare investors [2] Group 2 - The article does not provide specific financial data or performance metrics related to Tourmaline Bio or the broader biotech industry [1][3][4]